Combination of a novel HDAC6 inhibitor ACY-241 and anti-PD-L1 antibody enhances anti-tumor immunity and cytotoxicity in multiple myeloma

Leukemia. 2018 Mar;32(3):843-846. doi: 10.1038/leu.2017.322. Epub 2017 Nov 6.

Authors

A Ray¹, D S Das¹, Y Song¹, T Hideshima¹, Y-T Tai¹, D Chauhan¹, K C Anderson¹

Affiliation

¹ The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

No abstract available

Publication types

Letter
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

Antineoplastic Agents, Immunological / administration & dosage
Antineoplastic Combined Chemotherapy Protocols / adverse effects
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
B7-H1 Antigen / antagonists & inhibitors*
Histone Deacetylase 6 / antagonists & inhibitors*
Histone Deacetylase Inhibitors / administration & dosage
Humans
Multiple Myeloma / drug therapy*
Multiple Myeloma / immunology
Multiple Myeloma / metabolism
Treatment Outcome

Substances

Antineoplastic Agents, Immunological
B7-H1 Antigen
CD274 protein, human
Histone Deacetylase Inhibitors
Histone Deacetylase 6

Grants and funding